OMT Announces New Antibody Discovery Program
News Jul 10, 2012
Open Monoclonal Technology, Inc. (OMT) has announced an antibody discovery collaboration with Merck KGaA.
OMT and Merck KGaA have entered into a collaboration whereby OMT will use its OmniRats™ to generate antibodies against several targets selected by Merck KGaA.
Merck KGaA has the rights to further develop and commercialize the antibodies derived from the OmniRat™ as therapeutic and diagnostic products.
Under the terms of the agreement, OMT will receive upfront payment, success-based milestones, and royalties.
"We are pleased to be collaborating with Merck KGaA. OMT's OmniRat™ generates antibodies with great specificity, affinity and manufacturability. Our partners are looking for technologies that can eliminate time-consuming humanization of antibodies or optimization of leads identified using display technology. The OmniRat™ can save significant development time and is available for all targets", said Roland Buelow, Founder and CEO of OMT.
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Gut Bacteria Latest Ally in Fight Against SepsisNews
Sepsis occurs when the body's response to the spread of bacteria or toxins to the bloodstream damages tissues and organs. The fight against sepsis could get a helping hand from a surprising source: gut bacteria. Researchers found that giving mice particular microbes increased blood levels of immunoglobulin A (IgA) antibodies, which protected against the kind of widespread bacterial invasion that leads to sepsis.READ MORE